Opioid Use Disorder: Consideration of Medication-Assisted Treatment for Real-World Challenges During the Coronavirus Pandemic

Opioid Use Disorder: Consideration of Medication-Assisted Treatment for Real-World Challenges During the Coronavirus Pandemic

On-Demand Webcast

Marc Fishman, MD
Medical Director
Maryland Treatment Centers
Assistant Professor of Psychiatry and Behavioral Sciences
Johns Hopkins University School of Medicine
Baltimore, Maryland


This webcast is based on live proceedings from the 2020 National Conference on Addiction Disorders (NCAD) Virtual Conference.

Provided by North American Center for Continuing Medical Education, LLC, an HMP Company.

For questions regarding this educational activity, please call 609-371-1137 or email info@naccme.com.


This on-demand activity is designed for the full multidisciplinary addiction management team and all other stakeholders in addiction management, including: psychiatrists, nurse practitioners (NPs), physician assistants (PAs), psychiatric nurses, psychologists, therapists, counselors, social workers, addiction management specialists, executive-level decision-makers at mental health and substance use treatment organizations, public health officials, and community advocates.


After participating in this activity, participants should be better able to:

  • Discuss guideline recommendations for the successful implementation of MOUD
  • Compare benefits and challenges associated with the use of approved medications for the treatment of OUD
  • Identify new MOUD formulations recently introduced or in the pipeline
  • Identify new medications and medication combinations that could be used to enhance the effectiveness of MOUD
  • Identify MOUD delivery strategies that could be used to overcome barriers to patient engagement
  • Review implementation strategies to address patient access to MOUD during the coronavirus pandemic
claiming crediT

To be eligible for credit, participants must complete the online activityand the evaluation.. Upon completing the activity, there will be instructions on how to print a certificate or other documentation of credit.

Release Date: September 17, 2020
Expiration Date: September 17, 2021
Estimated Time to Complete: 1 hour

There is no fee associated with this activity.


NACCME would like to thank the following companies who have supported the "Opioid Use Disorder: Consideration of Medication-Assisted Treatment for Real-World Challenges During the Coronavirus Pandemic" through educational grants and/or in-kind support: Indivior Inc. and Addiction Professional


    In support of improving patient care, NACCME is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.


NACCME designates this internet enduring activity for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


This on-demand, knowledge-based activity (UAN JA0006201-0000-20-170-H01-P) has been approved for a maximum of 1.00 contact hours (0.01 CEUs). 

The certificate is not the official record of your participation in the activity. The official record of credit will be the information in CPE Monitor system. The deadline to claim credit is 60 days after activity. Following ACPE Policy, NACCME will not be able to report your claimed credit to CPE Monitor after this 60-day period. Eligibility for pharmacy credit is contingent upon the successful completion of a post-test and/or evaluation for each activity or session attended.


This continuing nursing education activity awards 1.00 contact hours.

Provider approved by the California Board of Registered Nursing, Provider #13255 for 1.00 contact hours. 


NACCME has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with the AAPA CME Criteria. This activity is designated for 1.00 AAPA Category 1 credit(s). PAs should only claim credit commensurate with the extent of their participation.


As a Jointly Accredited Organization, North American Center for Continuing Medical Education, LLC (NACCME) is approved by the American Psychological Association to sponsor continuing education for psychologists. NACCME maintains responsibility for this program and its content. Variable credit for partial attendance may not be awarded. Full attendance is required for all CE activities.

Instructional Level: Advanced

This activity will award 1.00 continuing education credit.


NACCME is approved to offer social work continuing education by the Association of Social Work Boards (ASWB) Approved Continuing Education (ACE) program. Organizations, not individual courses, are approved under this program. State and provincial regulatory boards have the final authority to determine whether an individual course may be accepted for continuing education credit. NACCME maintains responsibility for this course. Social workers completing this course receive 1.00 [Beginner/Intermediate/Advanced] continuing education credit.


This course has been approved by NACCME, LLC, as a NAADAC Approved Education Provider, for educational credits. NAADAC Provider #182840.  NACCME is responsible for all aspects of the programming.


This continuing medical education activity may include device or medicine brand names for participant clarity purposes only, due to the presence of different branded versions of the same product. No product promotion or recommendation should be inferred.


This activity may contain information about experimental and other uses of drugs or devices that are not currently approved by the European Medicines Agency (EMA) of the European Union or the Food and Drug Administration (FDA) of the United States. Participants are strongly encouraged to consult approved product labeling for any drug or device mentioned in this activity before use. The opinions expressed during this activity are the opinions of the respective authors, presenters or moderators and do not necessarily reflect the opinions of NACCME.


The material presented and related discussions are not intended to be medical advice, and the presentation or discussion of such material is not intended to create and does not establish a physician-patient relationship. Medical advice of any nature should be sought from an individual’s own physician.

Neither NACCME nor any of its subsidiaries or affiliates is affiliated with, or formally endorsed by a medical society.

The opinions expressed in this educational activity are those of the faculty and are not attributable to NACCME or HMP. Clinical judgment must guide each professional in weighing the benefits of treatment against the risk of toxicity. Dosages, indications, and methods of use for products referred to in this activity are not necessarily the same as indicated in the package insert for each product, may reflect the clinical experience of the presenters, and may be derived from the professional literature or other clinical sources. Consult complete prescribing information before administering.


NACCME, LLC is an independent provider(s) of continuing medical education. NACCME, LLC has no proprietary or financial interest in medical or healthcare products over which the FDA (USA) or EMA (EU) has regulatory authority.

NACCME, LLC assures that all educational materials are reviewed to ensure for the absence of commercial bias, fair balance, scientific objectivity, and levels of evidence. The educational activity will not be influenced by commercial organizations and will not conflict with any other scheduled educational activities.

According to the disclosure policy of NACCME, faculty, editors, managers, and other individuals who are in a position to control content are required to disclose any relevant financial relationships with relevant commercial companies related to this activity. All relevant conflicts of interest that are identified are reviewed for potential conflicts of interest. If a conflict is identified, it is the responsibility of NACCME to initiate a mechanism to resolve the conflict. The existence of these interests or relationships is not viewed as implying bias or decreasing the value of the presentation.

Planning Committee

In addition to the faculty listed below, NACCME planners and staff include Chris Bowell, Sam Conforti, Doug Edwards, Nimma Ovwori, Randy Robbin and Greaton Sellers.

Chris Bolwell is a shareholder of GlaxoSmithKline. GlaxoSmithKline is not supporting this activity, nor does any content relate to their product/service.

No other NACCME planner or staff has a relevant relationship with any commercial interest.

NCAD Advisory Board
David R. Gastfriend, MD: Consultant—American Society of Addiction Medicine/RecoverySearch, Inc.; Royalty-- American Society of Addiction Medicine/RecoverySearch, Inc.; Other financial or material support—DynamiCare Health, Inc.
Mary P. Hauser, MA: Employee—Dominion Diagnostics
Robert Valuck, PhD, RPH, FNAP: Co-Founder and CEO—OpiSafe, Inc.
Carol Boyer, Tom Britton, DrPh, Allison Harden, MS, CPFS, NCPRSS, J. Gregory Hobelmann, MD, MPH, Philip T. McCabe, CSW, CAS, CDVC, DRCC, Carmen R. Nevarez MD, MPH, Maeve O'Neill, MEd, LCDC, LPC-S, CHC, CDWF/CDTLF, Crystal Smalldon, Zach Snitzer, Nick Stavros, MBA, and Mary Ryan Woods, RNC, LADC, MSHS disclosed no relevant financial relationships with any commercial interests.

The faculty has reported the following:

Marc Fishman: Consultant – Alkermes, American Society of Addiction Medicine; Drug Delivery LLC; National Drug Court Institute; US WorldMeds; Grant/Research Support - Alkermes

Dr. Fishman will be discussing the following use of unlabeled/unapproved drugs or devices: Brixadi for the treatment of OUD; off-label use of buprenorphine, XR-naltrexone, XR- buprenorphine, clonidine, and prazosin.

Brand names are included in this presentation for participant clarification purposes only.


North American Center for Continuing Medical Education (NACCME) complies with the legal requirements of the Americans with Disabilities Act and the rules and regulations thereof. If any participant in this educational activity is in need of accommodations, please call 609-371-1137.


NACCME protects the privacy of personal and other information regarding participants, educational partners, and joint providers. NACCME and our joint providers will not release personally identifiable information to a third party without the individual’s consent, except such information as is required for reporting purposes to the appropriate accrediting agency. NACCME maintains physical, electronic, and procedural safeguards that comply with federal regulations to guard your nonpublic personal information.

Copyright © 2020 by North American Center for Continuing Medical Education, LLC. All rights reserved. No part of this accredited continuing education activity may be reproduced or transmitted in any form or by any means, electronic or mechanical, without first obtaining permission from North American Center for Continuing Medical Education.